{
  "updated_at": "2026-02-02T14:00:00Z",
  "assets": {
    "Plozasiran": {
      "trials": {
        "PALISADE": {
          "asset": "Plozasiran",
          "trial": "PALISADE",
          "indication": "Familial Chylomicronemia Syndrome (FCS)",
          "presentation": "ESC 2024 Investor Webinar - PALISADE Phase 3 Results",
          "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
          "annotated_at": "2026-02-02T14:00:00Z",
          "figures": [
            {
              "id": "arwr-palisade-slide-30",
              "source": "ESC 2024 Investor Webinar - PALISADE Results",
              "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
              "slide_number": 30,
              "image_path": "/figures/arwr/palisade/slide-30.png",
              "figure_type": "bar_chart",
              "title": "Primary Endpoint: TG and APOC3 Reduction at Month 10",
              "description": "Bar chart showing median percent change from baseline in triglycerides and APOC3 protein levels at Month 10 (primary) and Month 10/12 average",
              "extracted_data": {
                "primary_endpoint": "Fasting TG change at Month 10",
                "treatment_25mg_result": "-80%",
                "treatment_50mg_result": "-78%",
                "placebo_result": "-17%",
                "p_value_25mg": "<0.0001",
                "p_value_50mg": "0.0002",
                "apoc3_reduction_25mg": "-93%",
                "apoc3_reduction_50mg": "-96%",
                "n_placebo": 19,
                "n_25mg": 26,
                "n_50mg": 24
              },
              "analysis": [
                "80% TG reduction significantly exceeds standard of care fibrates (30-50% reduction)",
                "Consistent robust effect across both 25mg and 50mg dose groups with similar efficacy",
                "Near-complete APOC3 knockdown (-93% to -96%) validates RNAi mechanism of action",
                "Highly significant p-values (<0.0001) demonstrate statistical robustness despite small sample size"
              ],
              "limitations": [
                "Small sample size (n=75 total)",
                "12-month primary endpoint duration"
              ],
              "competitive_context": "TG reduction superior to Ionis volanesorsen (~77%) and olezarsen (~60%). APOC3 knockdown comparable to ASO approaches but with better dosing convenience.",
              "citation_number": 1
            },
            {
              "id": "arwr-palisade-slide-31",
              "source": "ESC 2024 Investor Webinar - PALISADE Results",
              "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
              "slide_number": 31,
              "image_path": "/figures/arwr/palisade/slide-31.png",
              "figure_type": "line_chart",
              "title": "Durability of Response: TG and APOC3 Reduction Over 12 Months",
              "description": "Time course line charts showing sustained triglyceride and APOC3 reductions from baseline over 12 months of quarterly dosing",
              "extracted_data": {
                "primary_endpoint": "TG and APOC3 change over time",
                "tg_month1_result": "-70%",
                "tg_month10_result": "-80%",
                "tg_month12_result": "-75%",
                "apoc3_sustained": "-90% throughout",
                "placebo_tg": "Near 0% change",
                "dosing_interval": "Q3M (every 3 months)"
              },
              "analysis": [
                "Rapid onset of action with ~70% TG reduction by Month 1 after first dose",
                "Durable effect maintained through Month 12 with quarterly dosing (Q3M)",
                "Sustained APOC3 knockdown throughout treatment period validates mechanism durability",
                "Time course supports convenient quarterly dosing interval for chronic treatment"
              ],
              "limitations": [
                "12-month data only",
                "Variability increases in later timepoints (wider error bars)"
              ],
              "competitive_context": "Quarterly dosing superior to volanesorsen (weekly) and potentially olezarsen (monthly). Sustained effect differentiates from fibrates requiring daily dosing.",
              "citation_number": 1
            },
            {
              "id": "arwr-palisade-slide-34",
              "source": "ESC 2024 Investor Webinar - PALISADE Results",
              "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
              "slide_number": 34,
              "image_path": "/figures/arwr/palisade/slide-34.png",
              "figure_type": "waterfall_plot",
              "title": "Individual Patient TG Response and Clinically Meaningful Thresholds",
              "description": "Waterfall plot showing percent change in TG at Month 10 for each patient, with responder analysis table showing proportion achieving clinical thresholds",
              "extracted_data": {
                "primary_endpoint": "Individual TG change at Month 10",
                "responders_below_500": "50% (25mg), 46% (50mg) vs 5% placebo",
                "responders_below_880": "75% (25mg), 55% (50mg) vs 21% placebo",
                "responders_below_1000": "83% (25mg), 68% (50mg) vs 32% placebo",
                "all_treated_responded": "Nearly all plozasiran patients achieved >50% reduction",
                "placebo_variability": "High variability, some increased"
              },
              "analysis": [
                "Consistent individual responses - nearly all plozasiran patients achieved meaningful TG reductions",
                "75% of 25mg patients achieved TG <880 mg/dL threshold associated with reduced pancreatitis risk",
                "Clear separation between treatment and placebo groups across all thresholds",
                "Individual patient data demonstrates mechanism reliability and low non-responder rate"
              ],
              "limitations": [
                "Small sample sizes per group",
                "Threshold definitions vary in clinical significance"
              ],
              "competitive_context": "Responder rates comparable to or better than volanesorsen Phase 3 data. Consistent individual responses suggest predictable clinical benefit.",
              "citation_number": 1
            },
            {
              "id": "arwr-palisade-slide-35",
              "source": "ESC 2024 Investor Webinar - PALISADE Results",
              "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
              "slide_number": 35,
              "image_path": "/figures/arwr/palisade/slide-35.png",
              "figure_type": "kaplan_meier",
              "title": "Reduction in Acute Pancreatitis Events",
              "description": "Kaplan-Meier curve showing time to first acute pancreatitis event over 52 weeks, demonstrating 83% reduction in pancreatitis risk",
              "extracted_data": {
                "primary_endpoint": "Time to first acute pancreatitis event",
                "placebo_events": "5 events in 25 patients (20%)",
                "plozasiran_events": "2 events in 50 patients (4%)",
                "odds_ratio": "0.17",
                "odds_ratio_ci": "0.03-0.94",
                "p_value": "0.029",
                "relative_risk_reduction": "83%"
              },
              "analysis": [
                "83% relative risk reduction in acute pancreatitis - the most feared complication of FCS",
                "Statistically significant (p=0.029) despite small event numbers due to magnitude of effect",
                "Clinical outcome endpoint strengthens regulatory and commercial positioning",
                "Pancreatitis reduction directly addresses primary unmet need in FCS patient population"
              ],
              "limitations": [
                "Low absolute event numbers (7 total events)",
                "Wide confidence interval due to small sample",
                "52-week follow-up only"
              ],
              "competitive_context": "First APOC3-targeting therapy to demonstrate pancreatitis reduction in randomized trial. Volanesorsen showed similar trends but with safety concerns.",
              "citation_number": 1
            },
            {
              "id": "arwr-palisade-slide-36",
              "source": "ESC 2024 Investor Webinar - PALISADE Results",
              "source_url": "https://ir.arrowheadpharma.com/events/event-details/investor-conference-call-plozasiran-palisade-results-esc-2024",
              "slide_number": 36,
              "image_path": "/figures/arwr/palisade/slide-36.png",
              "figure_type": "table",
              "title": "Summary of Adverse Events",
              "description": "Safety summary table showing treatment-emergent adverse events (TEAEs) across placebo and plozasiran groups",
              "extracted_data": {
                "any_teae_placebo": "20 patients (80%)",
                "any_teae_25mg": "23 patients (88%)",
                "any_teae_50mg": "20 patients (83%)",
                "serious_teae_placebo": "7 (28%)",
                "serious_teae_25mg": "5 (19%)",
                "serious_teae_50mg": "2 (8%)",
                "discontinuations_placebo": "6 (24%)",
                "discontinuations_25mg": "3 (12%)",
                "discontinuations_50mg": "2 (8%)",
                "deaths": "0 in all groups",
                "platelet_effect": "No reductions in platelet counts"
              },
              "analysis": [
                "Favorable safety profile with lower serious TEAEs in plozasiran vs placebo (likely due to pancreatitis reduction)",
                "No platelet reductions - key differentiator vs volanesorsen which has boxed warning for thrombocytopenia",
                "Fewer premature discontinuations with plozasiran (8-12%) vs placebo (24%)",
                "No deaths in any treatment group; no hepatotoxicity signals observed"
              ],
              "limitations": [
                "Small sample size limits detection of rare events",
                "12-month exposure data only"
              ],
              "competitive_context": "Clean safety profile differentiates from volanesorsen (thrombocytopenia boxed warning, platelet monitoring required). Supports broader use in clinical practice.",
              "citation_number": 1
            }
          ]
        }
      }
    }
  }
}
